Skip to main content
Dx & Vx Co., Ltd. logo

Dx & Vx Co., Ltd. — Investor Relations & Filings

Ticker · 180400 ISIN · KR7180400004 KO Manufacturing
Open in API
Filings indexed 474 across all filing types
Latest filing 2022-07-29 Annual Report
Country KR South Korea
Listing KO 180400

About Dx & Vx Co., Ltd.

https://www.dxvx.com/

Dx & Vx Co., Ltd. is a bio-healthcare company specializing in diagnostics and vaccine development. Its diagnostics division offers molecular diagnostic solutions, genomics and bioinformatics services, and customized companion diagnostics (CDx), leveraging an AI-based genome analysis platform. The company's therapeutic pipeline is centered on an innovative mRNA vaccine platform designed for long-term storage at room temperature. Key development areas include vaccines for infectious diseases, immuno-therapeutic cancer vaccines, oral treatments for obesity, and therapies for eye conditions. Additionally, Dx & Vx provides contract development, manufacturing, and sales organization (CDMO/CSO) services and commercializes microbiome-based products and health supplements.

Recent filings

Filing Released Lang Actions
[기재정정]사업보고서 (2021.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) which is the Korean equivalent of an Annual Report (10-K). It contains detailed financial data, business descriptions, management discussions, and governance information for the fiscal year. It is a comprehensive report rather than an announcement or a summary. FY 2021
2022-07-29 Korean
임시주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '임시주주총회결과' (Extraordinary General Meeting Results) and details the outcome of specific agenda items (voting results) from a shareholder meeting held on 2022-07-08. It explicitly lists the resolutions passed ('원안대로 가결'). This fits the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2022-07-08 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically identified as a '정정신고' (Correction Report). It details the granting of stock options to directors and executives, including the number of shares, exercise price, and valuation methodology. Since this is a specific regulatory disclosure regarding capital structure and executive compensation instruments (stock options) filed with the financial authorities, it falls under the category of 'Regulatory Filings' (RNS) as it does not fit into the more specific categories like 'Director's Dealing' (which is for trades) or 'Remuneration Information' (which is for proxy statements).
2022-07-08 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used by companies to solicit proxies from shareholders for an upcoming general meeting. It contains details about the meeting agenda, such as changes to the articles of incorporation and the granting of stock options. This document type is specifically categorized as a Proxy Solicitation & Information Statement (PSI) in the provided schema.
2022-06-24 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of Extraordinary General Meeting of Shareholders' (임시주주총회 소집통지서) for the company DXVX. It contains the meeting agenda, date, location, and detailed management information including board activities, remuneration, and business overview. This type of document is a standard proxy statement/notice for a shareholder meeting, which falls under the 'Proxy Solicitation & Information Statement' category.
2022-06-23 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to directors and employees, including the number of shares, exercise price, and legal basis. This type of disclosure regarding capital structure changes and equity-based compensation falls under the category of Regulatory Filings (RNS) as it is a specific corporate disclosure required by the exchange, and does not fit into more specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for capital changes).
2022-06-21 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.